Today's Challenge
Problems will always arise, and establishing a right-first-time (RFT) environment is a one-time investment to deal with this inevitability.
- See more at: https://www.parexel.com/regulatoryportal?utm_source=HBRprintedURL&utm_medium=print&utm_campaign=regulatoryhub#sthash.pG36KtGB.dpuf
Read Full Release
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Illumina, Inc.(NASDAQ:ILMN), the global leader in DNA sequencing and array-based technologies, today announced a strategic collaboration, that aims to integrate Illumina’s sequencing systems for large-scale analysis of genetic variation and function and Philips’ IntelliSpace Genomics clinical informatics platform, and to coordinate marketing and sales of the resulting solutions. Philips and Illumina will also seek to engage in clinical research collaborations with health systems in the US who want to develop precision medicine programs in oncology.
Read Full Release
Boston Millennia Partners Invests in Cota, Inc.
Boston, MA, December 2016, Boston Millennia Partners is pleased to announce its investment in Cota, Inc. as part of an $18 million growth equity round. Cota is a New York City based cancer outcomes and data tracking company that uses a patented digital classification system to assess patient results on specific treatment protocols. Cota’s customers include pharmaceutical companies, healthcare providers and insurance companies. The company has partnerships with several major pharmaceutical companies in the U.S. including Novartis and Celgene, and with data provider Foundation Medicine. The company has received strategic investments from Novartis, Celgene, Foundation Medicine and Horizon Healthcare.
Read Full Release
Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that it has finalized its contract with Express Scripts, the largest pharmacy benefits management (PBM) in the United States. Pursuant to the contract, Xtampza ER is covered on the 2017 Express Scripts’ National Preferred Formulary.
Read Full Release
COLL announced another formulary “win” for Xtampza following successful contracting with ESRX, the largest US pharmacy benefits manager (PBM). Starting January 1, 2017, Xtampza will be added to ESRX’s formulary as a preferred brand with access to another 28M commercial lives. Based on steady progress with the launch and managed care wins, we continue to believe that Xtampza Rxs are positioned for an inflection in 1H17 and see the drug as a $400M+ peak product.
Read Full Release
BOSTON–(BUSINESS WIRE)–December 15, 2016–Boston Millennia Partners is pleased to announce its investment in Cota, Inc. as part of an $18 million growth equity round. Cota is a New York City based cancer outcomes and data tracking company that uses a patented digital classification system to assess patient results on specific treatment protocols. Cota’s customers include pharmaceutical companies, healthcare providers and insurance companies. The company has partnerships with several major pharmaceutical companies in the U.S. including Novartis and Celgene, and with data provider Foundation Medicine. The company has received strategic investments from Novartis, Celgene, Foundation Medicine and Horizon Healthcare.
Read Full Release
BC Platforms, a world leader in genomic data management solutions, today announced that it will collaborate with Microsoft to provide integrated genomic data management solutions in the cloud to Codigo46. Codigo46, an emerging Mexican company, is building and managing the largest biobank in Latin-America in co-operation with Mexican health and research authorities. Codigo46 will genotype one million Mexican subjects in the next three years for the purpose of delivering personalized medicine benefits to patients. BC Platforms signed a partnership with Codigo46 in July 2016.
Read Full Release
The investment is a significant milestone in BC Platforms’ success and growth in North America as we roll-out our US expansion with headquarters in Boston. The Boston area boasts nearly 30,000 scientists and other workers directly involved in biotech, pharmaceutical and clinical research, the highest concentration of life-science research workers in the U.S. We are glad to have BMP as a partner to facilitate our ambitious development goals in the No. 1 U.S. life science hub.
Read Full Release
ACG Boston's regular networking breakfast returns to Serafina in Boston's financial district. Open to all, the Networking Breakfast is ACG Boston's signature event, where M&A professionals come to network and hear industry experts share their outlook, opinions, successes and failures.
Join New England's M&A community on November 17 to hear a panel discussion on the current state of the VC market -- how the industry has evolved and where it's headed in the future.
Read Full Release
